-
(
DengS
XuY
AnG
, et al. Features of extramedullary
disease of multiple myeloma: high frequency of p53 deletion and poor
survival: a retrospective single-center study of 834 cases.
Clin Lymphoma Myeloma Leuk.
2015;15:286-291.25640025)
DengS
XuY
AnG
, et al. Features of extramedullary
disease of multiple myeloma: high frequency of p53 deletion and poor
survival: a retrospective single-center study of 834 cases.
Clin Lymphoma Myeloma Leuk.
2015;15:286-291.25640025
DengS
XuY
AnG
, et al. Features of extramedullary
disease of multiple myeloma: high frequency of p53 deletion and poor
survival: a retrospective single-center study of 834 cases.
Clin Lymphoma Myeloma Leuk.
2015;15:286-291.25640025,
DengS
XuY
AnG
, et al. Features of extramedullary
disease of multiple myeloma: high frequency of p53 deletion and poor
survival: a retrospective single-center study of 834 cases.
Clin Lymphoma Myeloma Leuk.
2015;15:286-291.25640025
-
S.
Deng,
Yan
Xu,
G.
An,
W.
Sui,
D.
Zou,
Yao-zhong
Zhao,
J.
Qi,
Fei
Li,
M.
Hao,
L.
Qiu
(2015)
Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases.
Clinical lymphoma, myeloma & leukemia, 15 5
-
D.
Fotiou,
M.
Dimopoulos,
E.
Kastritis
(2018)
How We Manage Patients with Plasmacytomas
Current Hematologic Malignancy Reports, 13
-
(
HeJ
YueX
HeD
, et al. Multiple extramedullary-bone
related and/or extramedullary extraosseous are independent poor prognostic
factors in patients with newly diagnosed multiple myeloma.
Front Oncol.
2021;11:668099.34307138)
HeJ
YueX
HeD
, et al. Multiple extramedullary-bone
related and/or extramedullary extraosseous are independent poor prognostic
factors in patients with newly diagnosed multiple myeloma.
Front Oncol.
2021;11:668099.34307138
HeJ
YueX
HeD
, et al. Multiple extramedullary-bone
related and/or extramedullary extraosseous are independent poor prognostic
factors in patients with newly diagnosed multiple myeloma.
Front Oncol.
2021;11:668099.34307138,
HeJ
YueX
HeD
, et al. Multiple extramedullary-bone
related and/or extramedullary extraosseous are independent poor prognostic
factors in patients with newly diagnosed multiple myeloma.
Front Oncol.
2021;11:668099.34307138
-
N.
Gagelmann,
Diderik-Jan
Eikema,
L.
Koster,
D.
Caillot,
P.
Pioltelli,
Juan
Lleonart,
P.
Reményi,
D.
Blaise,
N.
Schaap,
M.
Trněný,
J.
Passweg,
Rocío
Porras,
J.
Cahn,
M.
Musso,
X.
Poiré,
R.
Fenk,
M.
Itälä-Remes,
V.
Pavone,
L.
Fouillard,
J.
Maertens,
D.
Bron,
A.
Pouli,
W.
Schroyens,
S.
Schönland,
L.
Garderet,
I.
Yakoub-Agha,
N.
Kröger
(2019)
Tandem autologous stem cell transplantation improves outcome in newly diagnosed multiple myeloma with extramedullary disease and high-risk cytogenetics: a study from the Chronic Malignancies Working Party of EBMT.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
-
(
SevcikovaS
MinarikJ
StorkM
JelinekT
PourL
HajekR.
Extramedullary disease in multiple myeloma—controversies and
future directions. Blood Rev.
2019;36:32-39.31005420)
SevcikovaS
MinarikJ
StorkM
JelinekT
PourL
HajekR.
Extramedullary disease in multiple myeloma—controversies and
future directions. Blood Rev.
2019;36:32-39.31005420
SevcikovaS
MinarikJ
StorkM
JelinekT
PourL
HajekR.
Extramedullary disease in multiple myeloma—controversies and
future directions. Blood Rev.
2019;36:32-39.31005420,
SevcikovaS
MinarikJ
StorkM
JelinekT
PourL
HajekR.
Extramedullary disease in multiple myeloma—controversies and
future directions. Blood Rev.
2019;36:32-39.31005420
-
M.
Beksaç,
G.
Seval,
N.
Kanellias,
D.
Coriu,
L.
Rosiñol,
G.
Ozet,
V.
Goranova-Marinova,
A.
Unal,
J.
Bila,
H.
Ozsan,
A.
Ivanaj,
Lejla
Balić,
E.
Kastritis,
J.
Bladé,
M.
Dimopoulos
(2019)
A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome
Haematologica, 105
-
V.
Montefusco,
F.
Gay,
S.
Spada,
L.
Paoli,
F.
Raimondo,
R.
Ribolla,
C.
Musolino,
F.
Patriarca,
P.
Musto,
P.
Galieni,
S.
Ballanti,
C.
Nozzoli,
N.
Cascavilla,
D.
Ben-yehuda,
A.
Nagler,
R.
Hájek,
M.
Offidani,
A.
Liberati,
P.
Sonneveld,
M.
Cavo,
P.
Corradini,
M.
Boccadoro
(2019)
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs
Haematologica, 105
-
(
BeksacM
SevalGC
KanelliasN
, et al. A real world multicenter
retrospective study on extramedullary disease from Balkan Myeloma Study
Group and Barcelona University: analysis of parameters that improve
outcome. Haematologica.
2020;105:201-208.31278209)
BeksacM
SevalGC
KanelliasN
, et al. A real world multicenter
retrospective study on extramedullary disease from Balkan Myeloma Study
Group and Barcelona University: analysis of parameters that improve
outcome. Haematologica.
2020;105:201-208.31278209
BeksacM
SevalGC
KanelliasN
, et al. A real world multicenter
retrospective study on extramedullary disease from Balkan Myeloma Study
Group and Barcelona University: analysis of parameters that improve
outcome. Haematologica.
2020;105:201-208.31278209,
BeksacM
SevalGC
KanelliasN
, et al. A real world multicenter
retrospective study on extramedullary disease from Balkan Myeloma Study
Group and Barcelona University: analysis of parameters that improve
outcome. Haematologica.
2020;105:201-208.31278209
-
M.
Varettoni,
A.
Corso,
G.
Pica,
S.
Mangiacavalli,
C.
Pascutto,
M.
Lazzarino
(2010)
Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients.
Annals of oncology : official journal of the European Society for Medical Oncology, 21 2
-
(
MontefuscoV
GayF
SpadaS
, et al. Outcome of paraosseous
extra-medullary disease in newly diagnosed multiple myeloma patients treated
with new drugs. Haematologica.
2020;105:193-200.31221778)
MontefuscoV
GayF
SpadaS
, et al. Outcome of paraosseous
extra-medullary disease in newly diagnosed multiple myeloma patients treated
with new drugs. Haematologica.
2020;105:193-200.31221778
MontefuscoV
GayF
SpadaS
, et al. Outcome of paraosseous
extra-medullary disease in newly diagnosed multiple myeloma patients treated
with new drugs. Haematologica.
2020;105:193-200.31221778,
MontefuscoV
GayF
SpadaS
, et al. Outcome of paraosseous
extra-medullary disease in newly diagnosed multiple myeloma patients treated
with new drugs. Haematologica.
2020;105:193-200.31221778
-
M.
Bhutani,
D.
Foureau,
S.
Atrash,
P.
Voorhees,
S.
Usmani
(2019)
Extramedullary multiple myeloma
Leukemia, 34
-
Jingsong
He,
Xiaoyan
Yue,
D.
He,
Yi
Zhao,
Yang
Yang,
G.
Zheng,
E.
Zhang,
Xiaoyan
Han,
Wen-jun
Wu,
Li
Yang,
Jing
Chen,
Z.
Cai
(2021)
Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma
Frontiers in Oncology, 11
-
S.
Ševčíková,
J.
Minařík,
M.
Štork,
T.
Jelínek,
L.
Pour,
R.
Hájek
(2019)
Extramedullary disease in multiple myeloma - controversies and future directions.
Blood reviews, 36
-
N.
Gagelmann,
Diderik-Jan
Eikema,
S.
Iacobelli,
L.
Koster,
H.
Nahi,
A.
Stoppa,
T.
Masszi,
D.
Caillot,
S.
Lenhoff,
M.
Udvardy,
C.
Crawley,
W.
Arcese,
C.
Mariette,
A.
Hunter,
X.
Leleu,
M.
Schipperus,
M.
Delforge,
P.
Pioltelli,
J.
Snowden,
M.
Itälä-Remes,
M.
Musso,
A.
Biezen,
L.
Garderet,
N.
Kröger
(2018)
Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT
Haematologica, 103
-
(
ShinHJ
KimK
LeeJW
, et al. Comparison of outcomes after
autologous stem cell transplantation between myeloma patients with skeletal
and soft tissue plasmacytoma. Eur J
Haematol.
2014;93:414-421.24813053)
ShinHJ
KimK
LeeJW
, et al. Comparison of outcomes after
autologous stem cell transplantation between myeloma patients with skeletal
and soft tissue plasmacytoma. Eur J
Haematol.
2014;93:414-421.24813053
ShinHJ
KimK
LeeJW
, et al. Comparison of outcomes after
autologous stem cell transplantation between myeloma patients with skeletal
and soft tissue plasmacytoma. Eur J
Haematol.
2014;93:414-421.24813053,
ShinHJ
KimK
LeeJW
, et al. Comparison of outcomes after
autologous stem cell transplantation between myeloma patients with skeletal
and soft tissue plasmacytoma. Eur J
Haematol.
2014;93:414-421.24813053
-
R.
Çiftçiler,
H.
Göker,
H.
Demiroğlu,
S.
Aksu,
N.
Sayınalp,
I.
Haznedaroglu,
Ü.
Malkan,
Y.
Büyükaşık,
O.
Özcebe
(2019)
Evaluation of the Survival Outcomes of Multiple Myeloma Patients According to Their Plasmacytoma Presentation at Diagnosis
Turkish Journal of Hematology, 37
-
L.
Rosiñol,
M.
Beksaç,
E.
Zamagni,
N.
Donk,
K.
Anderson,
A.
Badros,
J.
Caers,
M.
Cavo,
M.
Dimopoulos,
A.
Dispenzieri,
H.
Einsele,
M.
Engelhardt,
C.
Larrea,
G.
Gahrton,
F.
Gay,
R.
Hájek,
V.
Hungria,
A.
Jurczyszyn,
N.
Kröger,
R.
Kyle,
F.
Costa,
X.
Leleu,
S.
Lentzsch,
M.
Mateos,
G.
Merlini,
M.
Mohty,
P.
Moreau,
L.
Rasche,
D.
Reece,
O.
Sezer,
P.
Sonneveld,
S.
Usmani,
K.
Vanderkerken,
D.
Vesole,
A.
Waage,
S.
Zweegman,
P.
Richardson,
J.
Bladé
(2021)
Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations
British Journal of Haematology, 194
-
(
ÇiftçilerR
GökerH
DemiroğluH
, et al. Evaluation of the survival
outcomes of multiple myeloma patients according to their plasmacytoma
presentation at diagnosis. Turk J Haematol.
2020;37:256-262.31833716)
ÇiftçilerR
GökerH
DemiroğluH
, et al. Evaluation of the survival
outcomes of multiple myeloma patients according to their plasmacytoma
presentation at diagnosis. Turk J Haematol.
2020;37:256-262.31833716
ÇiftçilerR
GökerH
DemiroğluH
, et al. Evaluation of the survival
outcomes of multiple myeloma patients according to their plasmacytoma
presentation at diagnosis. Turk J Haematol.
2020;37:256-262.31833716,
ÇiftçilerR
GökerH
DemiroğluH
, et al. Evaluation of the survival
outcomes of multiple myeloma patients according to their plasmacytoma
presentation at diagnosis. Turk J Haematol.
2020;37:256-262.31833716
-
P.
Sonneveld,
H.
Goldschmidt,
L.
Rosiñol,
J.
Bladé,
J.
Lahuerta,
M.
Cavo,
P.
Tacchetti,
E.
Zamagni,
M.
Attal,
H.
Lokhorst,
A.
Desai,
A.
Cakana,
K.
Liu,
H.
Velde,
D.
Esseltine,
P.
Moreau
(2013)
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 26
-
(
VarettoniM
CorsoA
PicaG
MangiacavalliS
PascuttoC
LazzarinoM.
Incidence, presenting features and outcome of extramedullary
disease in multiple myeloma: a longitudinal study on 1003 consecutive
patients. Ann Oncol.
2010;21:325-330.19633044)
VarettoniM
CorsoA
PicaG
MangiacavalliS
PascuttoC
LazzarinoM.
Incidence, presenting features and outcome of extramedullary
disease in multiple myeloma: a longitudinal study on 1003 consecutive
patients. Ann Oncol.
2010;21:325-330.19633044
VarettoniM
CorsoA
PicaG
MangiacavalliS
PascuttoC
LazzarinoM.
Incidence, presenting features and outcome of extramedullary
disease in multiple myeloma: a longitudinal study on 1003 consecutive
patients. Ann Oncol.
2010;21:325-330.19633044,
VarettoniM
CorsoA
PicaG
MangiacavalliS
PascuttoC
LazzarinoM.
Incidence, presenting features and outcome of extramedullary
disease in multiple myeloma: a longitudinal study on 1003 consecutive
patients. Ann Oncol.
2010;21:325-330.19633044
-
(
GagelmannN
EikemaDJ
KosterL
, et al. Tandem Autologous Stem Cell
Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with
Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic
Malignancies Working Party of the European Society for Blood and Marrow
Transplantation. Biol Blood Marrow
Transplant.
2019;25:2134-2142.31288095)
GagelmannN
EikemaDJ
KosterL
, et al. Tandem Autologous Stem Cell
Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with
Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic
Malignancies Working Party of the European Society for Blood and Marrow
Transplantation. Biol Blood Marrow
Transplant.
2019;25:2134-2142.31288095
GagelmannN
EikemaDJ
KosterL
, et al. Tandem Autologous Stem Cell
Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with
Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic
Malignancies Working Party of the European Society for Blood and Marrow
Transplantation. Biol Blood Marrow
Transplant.
2019;25:2134-2142.31288095,
GagelmannN
EikemaDJ
KosterL
, et al. Tandem Autologous Stem Cell
Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with
Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic
Malignancies Working Party of the European Society for Blood and Marrow
Transplantation. Biol Blood Marrow
Transplant.
2019;25:2134-2142.31288095
-
(
SonneveldP
GoldschmidtH
RosinolL
, et al. Bortezomib-based versus
nonbortezomib-based induction treatment before autologous stem-cell
transplantation in patients with previously untreated multiple myeloma: a
meta-analysis of phase III randomized, controlled trials.
J Clin Oncol.
2013;31:3279-3287.23897961)
SonneveldP
GoldschmidtH
RosinolL
, et al. Bortezomib-based versus
nonbortezomib-based induction treatment before autologous stem-cell
transplantation in patients with previously untreated multiple myeloma: a
meta-analysis of phase III randomized, controlled trials.
J Clin Oncol.
2013;31:3279-3287.23897961
SonneveldP
GoldschmidtH
RosinolL
, et al. Bortezomib-based versus
nonbortezomib-based induction treatment before autologous stem-cell
transplantation in patients with previously untreated multiple myeloma: a
meta-analysis of phase III randomized, controlled trials.
J Clin Oncol.
2013;31:3279-3287.23897961,
SonneveldP
GoldschmidtH
RosinolL
, et al. Bortezomib-based versus
nonbortezomib-based induction treatment before autologous stem-cell
transplantation in patients with previously untreated multiple myeloma: a
meta-analysis of phase III randomized, controlled trials.
J Clin Oncol.
2013;31:3279-3287.23897961
-
(
PaubelleE
CoppoP
GarderetL
, et al. Complete remission with
bortezomib on plasmocytomas in an end-stage patient with refractory multiple
myeloma who failed all other therapies including hematopoietic stem cell
transplantation: possible enhancement of graft-vs-tumor
effect. Leukemia.
2005;19:1702-1704.16001088)
PaubelleE
CoppoP
GarderetL
, et al. Complete remission with
bortezomib on plasmocytomas in an end-stage patient with refractory multiple
myeloma who failed all other therapies including hematopoietic stem cell
transplantation: possible enhancement of graft-vs-tumor
effect. Leukemia.
2005;19:1702-1704.16001088
PaubelleE
CoppoP
GarderetL
, et al. Complete remission with
bortezomib on plasmocytomas in an end-stage patient with refractory multiple
myeloma who failed all other therapies including hematopoietic stem cell
transplantation: possible enhancement of graft-vs-tumor
effect. Leukemia.
2005;19:1702-1704.16001088,
PaubelleE
CoppoP
GarderetL
, et al. Complete remission with
bortezomib on plasmocytomas in an end-stage patient with refractory multiple
myeloma who failed all other therapies including hematopoietic stem cell
transplantation: possible enhancement of graft-vs-tumor
effect. Leukemia.
2005;19:1702-1704.16001088
-
E.
Paubelle,
P.
Coppo,
L.
Garderet,
L.
Azizi,
D.
Bories,
N.
Gorin,
L.
Fouillard
(2005)
Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect
Leukemia, 19
-
(
RosinolL
BeksacM
ZamagniE
, et al. Expert review on soft-tissue
plasmacytomas in multiple myeloma: definition, disease assessment and
treatment considerations. Br J Haematol.
2021;194:496-507.33724461)
RosinolL
BeksacM
ZamagniE
, et al. Expert review on soft-tissue
plasmacytomas in multiple myeloma: definition, disease assessment and
treatment considerations. Br J Haematol.
2021;194:496-507.33724461
RosinolL
BeksacM
ZamagniE
, et al. Expert review on soft-tissue
plasmacytomas in multiple myeloma: definition, disease assessment and
treatment considerations. Br J Haematol.
2021;194:496-507.33724461,
RosinolL
BeksacM
ZamagniE
, et al. Expert review on soft-tissue
plasmacytomas in multiple myeloma: definition, disease assessment and
treatment considerations. Br J Haematol.
2021;194:496-507.33724461
-
(
KumarL
GogiR
PatelAK
, et al. Multiple myeloma with
extramedullary disease: impact of autologous stem cell transplantation on
outcome. Bone Marrow Transplant.
2017;52:1473-1475.28805789)
KumarL
GogiR
PatelAK
, et al. Multiple myeloma with
extramedullary disease: impact of autologous stem cell transplantation on
outcome. Bone Marrow Transplant.
2017;52:1473-1475.28805789
KumarL
GogiR
PatelAK
, et al. Multiple myeloma with
extramedullary disease: impact of autologous stem cell transplantation on
outcome. Bone Marrow Transplant.
2017;52:1473-1475.28805789,
KumarL
GogiR
PatelAK
, et al. Multiple myeloma with
extramedullary disease: impact of autologous stem cell transplantation on
outcome. Bone Marrow Transplant.
2017;52:1473-1475.28805789
-
Ho-Jin
Shin,
Kihyun
Kim,
Ji
Lee,
Moo‐Kon
Song,
Je-Jung
Lee,
Ho-Sup
Lee,
W.
Lee,
S.
Kim,
J.
Chung
(2014)
Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma
European Journal of Haematology, 93
-
(
FotiouD
DimopoulosMA
KastritisE.
How we manage patients with plasmacytomas.
Curr Hematol Malig Rep.
2018;13:227-235.29667156)
FotiouD
DimopoulosMA
KastritisE.
How we manage patients with plasmacytomas.
Curr Hematol Malig Rep.
2018;13:227-235.29667156
FotiouD
DimopoulosMA
KastritisE.
How we manage patients with plasmacytomas.
Curr Hematol Malig Rep.
2018;13:227-235.29667156,
FotiouD
DimopoulosMA
KastritisE.
How we manage patients with plasmacytomas.
Curr Hematol Malig Rep.
2018;13:227-235.29667156
-
(
BhutaniM
FoureauDM
AtrashS
, et al. Extramedullary multiple
myeloma. Leukemia.
2020;34:1-20.31776467)
BhutaniM
FoureauDM
AtrashS
, et al. Extramedullary multiple
myeloma. Leukemia.
2020;34:1-20.31776467
BhutaniM
FoureauDM
AtrashS
, et al. Extramedullary multiple
myeloma. Leukemia.
2020;34:1-20.31776467,
BhutaniM
FoureauDM
AtrashS
, et al. Extramedullary multiple
myeloma. Leukemia.
2020;34:1-20.31776467
-
L.
Kumar,
R.
Gogi,
A.
Patel,
A.
Mookerjee,
R.
Sahoo,
P.
Malik,
A.
Sharma,
S.
Thulkar,
Ravi
Kumar,
A.
Biswas,
O.
Sharma,
R.
Gupta
(2017)
Multiple myeloma with extramedullary disease: impact of autologous stem cell transplantation on outcome
Bone Marrow Transplantation, 52